This month, the Biden administration announced its support for a waiver of intellectual property (IP) protections relating to the production of COVID-19 vaccines. Few would take issue with the purported goal of such a waiver—speeding access to these life-saving vaccines in nations still deep in the throes of this global pandemic, where demand for vaccines far outstrips their supply. But in reality, the waiver proposal creates far more problems than it solves, raising disputes under international IP agreements while failing to address the more significant logistical and supply chain obstacles to vaccine access.